1 However, many patients fail to receive timely PPCI because of geographical or logistical issues. In such cases, pharmacoinvasive strategy where fibrinolysis is followed by immediate Background-The Strategic Reperfusion Early After Myocardial Infarction trial and the French Registry of Acute STelevation or Non-ST-elevation Myocardial Infarction 2015 suggested that pharmacoinvasive strategy compares favorably with primary percutaneous coronary intervention (PPCI). We sought to assess the clinical impact of pharmacoinvasive strategy compared with PPCI in real-world patients with ST-segment-elevation myocardial infarction. Methods and Results-We used the Korea Acute Myocardial Infarction Registry to identify ST-segment-elevation myocardial infarction patients receiving either pharmacoinvasive strategy defined as fibrinolysis followed by percutaneous coronary intervention (rescue/urgent or routine elective; n=708) or PPCI (n=8878). Patients receiving facilitated percutaneous coronary intervention within 3 hours from fibrinolysis were excluded. Propensity-matched 12-month clinical outcome was compared. In the propensity-matched cohort (n=706 in each group), the pharmacoinvasive group had shorter time to reperfusion therapy (165 versus 241 minutes; P<0.001) and higher rate of pre-percutaneous coronary intervention Thrombolysis in Myocardial Infarction grade 3 (50.4% versus 13.7%; P<0.001). Incidences of major bleeding and stroke during hospitalization were not different. Twelve-month rates of death and major adverse cardiac events (composite of death, recurrent myocardial infarction, target-vessel revascularization, and coronary artery bypass graft surgery) were similar between pharmacoinvasive strategy and PPCI: 4.4% versus 4.1% and 7.5% versus 7.8%, respectively. Equipoise between pharmacoinvasive strategy and PPCI for 12-month major adverse cardiac events occurred when percutaneous coronary intervention-related delay was ≈100 minutes. Conclusions-ST-segment-elevation myocardial infarction patients receiving pharmacoinvasive treatment, compared with PPCI, had shorter time to reperfusion, higher culprit-vessel patency, and similar 12-month clinical outcome.
Pharmacoinvasive Strategy in ST-Elevation Myocardial Infarction
transfer to a percutaneous coronary intervention (PCI)-capable hospital for either rescue PCI, in case of failed fibrinolysis, or routine coronary angiography and PCI, in case of successful fibrinolysis, is a valid alternative. 2, 3 In contrast, facilitated PCI consisting of fibrinolysis followed by immediate planned PCI is not recommended because of increased risk of death, intracranial hemorrhage, and ischemic events. 4, 5 There are currently few large-scale studies that provide data regarding the efficacy of pharmacoinvasive strategy compared with PPCI in real-world STEMI patients. In the present study, we sought to evaluate the 12-month clinical outcome of patients with STEMI undergoing pharmacoinvasive strategy compared with PPCI using KAMIR (Korea Acute Myocardial Infarction Registry).
Methods

Study Population and Data Collection
The study population was derived from KAMIR between November 2005 and December 2011. KAMIR is the first nationwide, multicenter data-collection registry in Korea, designed to capture the outcomes of patients with acute myocardial infarction (MI). 6 We identified 9759 patients (≥18 years) with STEMI (<12 hours) eligible for either fibrinolysis or PPCI. All fibrinolysis procedures were performed in the in-hospital setting, and of 881 patients receiving fibrinolysis, 843 patients (96%) underwent coronary angiography and 726 patients underwent (82%) subsequent PCI. The study flow diagram is shown in Figure 1 .
The present study was conducted according to the Declaration of Helsinki. The institutional review board of all participating centers approved the study protocol. The approval number was 05-49 of Chonnam National University Hospital. Written informed consent was obtained from all participating patients.
Clinical End Points and Definitions
STEMI was defined as chest pain suggestive of myocardial ischemia for ≈30 minutes, ST-segment elevation >0.1 mV in ≥2 contiguous leads, or new or presumably new left bundle-branch block on the 12-lead ECG and elevated cardiac markers (creatine kinase-MB or troponin I/T). PPCI was defined as PCI within 12 hours of symptom onset in a patient not receiving fibrinolysis. 7 Time to start of reperfusion therapy was defined as time to intravenous injection of fibrinolytics and time to balloon inflation in patients treated with fibrinolysis and PPCI, respectively. Rescue PCI was defined as PCI mandated by persisting symptoms or persisting ST-segment elevation (failure to achieve ≈50% ST resolution) within 90 minutes after the administration of fibrinolysis. 8 Urgent PCI was defined as PCI undertaken at any time for worsening ischemia, hemodynamic instability, refractory ventricular arrhythmias, or recurrent ST-segment elevation that requires immediate coronary intervention. 8 Facilitated PCI was defined as fibrinolysis followed by immediate PCI (within 3 hours) irrespective of fibrinolytic success. 4, 9 Pharmacoinvasive strategy was defined as fibrinolysis followed by rescue or urgent PCI or by routine elective PCI (beyond 3 hours of fibrinolytic administration).
9 PCI-related delay was defined as the difference between the time from first medical contact (FMC) to balloon inflation and the time from FMC to the start of fibrinolytic therapy. 3 The primary end point of the study was the occurrence of major adverse cardiac events (MACE; composite of death from any cause, recurrent MI, target-vessel revascularization, and coronary artery bypass graft surgery) at 12 months. The secondary end points included death from any cause, recurrent MI, targetvessel revascularization, and coronary artery bypass graft surgery. Recurrent MI was defined as the recurrence of symptoms or the presence of ECG changes in association with a rise in cardiac markers above the upper limit of normal. Target-vessel revascularization was defined as a repeat PCI of any segment within the entire major coronary vessel proximal and distal to a target lesion, including the target lesion itself. Major bleeding was defined as type 3 or type 5 of the Bleeding Academic Research Consortium.
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WHAT IS KNOWN
• American College of Cardiology/American Heart Association guidelines recommend primary percutaneous coronary intervention (PCI) for patients with ST-segment-elevation myocardial infarction presenting ≤12 hours of symptom onset with a first medical contact-to-device time goal of ≤120 minutes.
• Facilitated PCI consisting of fibrinolysis followed by immediate planned PCI is not recommended because of increased risk of death, intracranial hemorrhage, and ischemic events.
• Pharmacoinvasive strategy where fibrinolysis is followed by immediate transfer to a PCI-capable hospital for either rescue PCI in case of failed fibrinolysis or routine coronary angiography and PCI in case of successful fibrinolysis may be a valid alternative to primary PCI and part of the primary reperfusion in patients with ST-segment-elevation myocardial infarction in whom long PCI-related delay is anticipated.
WHAT THE STUDY ADDS
• ST-segment-elevation myocardial infarction patients receiving pharmacoinvasive treatment, compared with primary PCI, had shorter symptom-to-reperfusion time, higher culprit-vessel patency, and similar 12-month clinical outcome.
• In real practice, many transferred patients with STsegment-elevation myocardial infarction do not receive timely primary PCI, while fibrinolytic therapy is underutilized. In such patients, pharmacoinvasive strategy may be instrumental in reducing total ischemic time and improving outcomes. Values are n (%) or mean±SD. CABG indicates coronary artery bypass grafting; CAD, coronary artery disease; EMS, emergency medical system; GRACE, Global Registry of Acute Coronary Events; LVEF, left ventricular ejection fraction; PCI, percutaneous coronary intervention; PI, pharmacoinvasive; and PPCI, primary percutaneous coronary intervention.
*Off-hours were defined as weeknights (Monday to Friday from 6:00 pm to 9:00 am), weekends, and holidays. Tables 1 through 3 : age, sex, body mass index, smoking status, hypertension, diabetes mellitus, dyslipidemia, prior history of MI, angina pectoris, PCI, and coronary artery bypass graft surgery, family history of coronary artery disease, time from symptom onset to FMC, typical chest pain at presentation, off-hour arrival, location of FMC, transfer admission, resuscitated cardiac arrest, systolic blood pressure, diastolic blood pressure, heart rate, Killip class, infarct location, left bundle branch block, second-or third-degree heart block, atrial fibrillation, use of aspirin, clopidogrel, unfractionated heparin, low molecular weight heparin, β-blocker, angiotensin-converting enzyme inhibitor or angiotensin-receptor blocker, diuretics, nitrates, and statin during hospitalization. The C statistic for the propensity model was 0.73, indicating fair ability to discriminate treatment groups.
Matching was performed using a greedy matching protocol (1:1 nearest neighbor matching without replacement) with a caliper width of 0.2 of the SD. 11 We were able to match 706 patients receiving pharmacoinvasive treatment to 706 patients receiving PPCI. We estimated standardized differences for all the 35 covariates before and after matching to assess balance of the covariates between the matched groups. After matching, none of the covariates showed a standardized difference exceeding 10%, suggesting that all measured covariates were well balanced. 12 Differences between the matched pairs were evaluated using the paired t test or the Wilcoxon signed-rank test for continuous variables and the McNemer test for categorical variables. The risks of clinical end points in the matched cohort were compared using a Cox proportional hazards regression model stratified on matched pairs, including factors deemed significant (P <0.1) by univariate analysis or considered clinically important in the multivariate model. We further tested the impact of pharmacoinvasive strategy on 12-month clinical outcome in multiple subgroups. For subgroup analysis, we repeated the same propensity score-matching process while matching on both the score and the subgroup variable, forcing exact matches on the subgroup characteristics. Conditional logistic regression was then used to identify treatment-subgroup interactions. PCI-related delay for a matched pair was calculated as the difference between the FMC to needle time and the FMC to balloon time in pharmacoinvasive and PPCI groups, respectively. Relationship between PCI-related delay and 12-month MACE was assessed as a linear regression model. All P values were 2 tailed, with statistical significance at <0.05. Statistical analyses were conducted using SPSS version 21 (SPSS Inc., Chicago, IL) and R version 3.1.2 (R Foundation for Statistical Computing, Vienna, Austria).
Results
Baseline Clinical, Procedural Characteristics, and Treatment During Hospitalization
In all patients (n=9586), pharmacoinvasive group (n=708) was younger, more often men, smokers, more likely to have typical chest pain, and off-hour arrival. PPCI group (n=8878) was more likely to have higher Global Registry of Acute Coronary Events score, diabetes mellitus, lower blood pressure, and higher Killip class (Table 1) . Pharmacoinvasive group had less complex lesions and higher rate of pre-PCI Thrombolysis In Myocardial Infarction grade 3 and more often received PCI with stenting, low molecular weight heparin, angiotensin inhibitors, and nitrates (Table 2) . PPCI group more often received glycoprotein IIb/IIIa inhibitor and β-blocker. The rate of post-PCI Thrombolysis In Myocardial Infarction grade 3 was, however, similar between 2 groups. In propensity-matched cohort (n=706 in each group), there were no significant differences in baseline clinical characteristics. Still, pharmacoinvasive group showed lower lesion complexity, higher rate of pre-PCI Thrombolysis In Myocardial Infarction grade 3 (13.7% versus 50.4%; P<0.001) and similar rate of post-PCI Thrombolysis In Myocardial Infarction grade 3 ( Table 2 ).
Time Delays
In all patients, time from symptom to FMC was significantly shorter in pharmacoinvasive group (Table 3) . Time from symptom onset to the initiation of reperfusion therapy and time from FMC to the start of reperfusion therapy were also shorter in pharmacoinvasive group. In propensity-matched cohort, time from symptom onset to FMC was no longer different. However, time from symptom onset to the start of reperfusion therapy (median 165 versus 241 minutes; P<0.001) and time from FMC to start of reperfusion therapy (median 80 versus 145 minutes; P<0.001) were still shorter in pharmacoinvasive groups.
Clinical Outcomes
In all patients, in-hospital mortality was lower in pharmacoinvasive group (Table 4) . Incidences of major bleeding and stroke during hospitalization were not different. Pharmacoinvasive group had lower rates of 12-month death and MACE. In propensity-matched cohort, there were no significant differences in in-hospital adverse event rates. Twelve-month mortality and MACE were not different between pharmacoinvasive strategy and PPCI-4.4% versus 4.1% and 7.5% versus 7.8%, respectively (Table 4 ; Figure 2 ). 
in ST-Elevation Myocardial Infarction
Subgroup analysis in propensity-matched cohort showed that the treatment effects of pharmacoinvasive strategy and PPCI for 12-month MACE in all subgroups were similar to those in the overall population ( Figure 3) . Relationship between PCI-related delay and clinical outcome was assessed as a linear regression model in propensity-matched cohort. For 12-month MACE, the point of equipoise between pharmacoinvasive strategy and PPCI was ≈100 minutes (Figure 4 ).
Discussion
The present study showed that STEMI patients receiving pharmacoinvasive treatment, compared with PPCI, had shorter symptom-to-reperfusion time, higher culprit-vessel patency, and similar 12-month clinical outcome, suggesting that pharmacoinvasive strategy may be a reasonable alternative to PPCI when long PCI-related delay is expected.
Currently, PPCI is the preferred treatment for STEMI patients who present within 12 hours of symptom onset. In case PPCI cannot be performed ≤120 minutes from the arrival to a non-PCI capable hospital, fibrinolysis should be administered ≤30 minutes of hospital arrival. 2, 3 Pharmacoinvasive strategy refers to fibrinolytic therapy either in a prehospital setting or at a non-PCI-capable hospital, followed by immediate transfer to a PCI capable hospital for early PCI. The rationale for this pharmacoinvasive approach is that initial fibrinolytic treatment is implemented to permit the Values are n (%). CABG indicates coronary artery bypass graft surgery; CI, confidence interval; HR, hazard ratio; MACE, major adverse cardiac events; MI, myocardial infarction; PCI, percutaneous coronary intervention; PI, pharmacoinvasive; PPCI, primary percutaneous coronary intervention; and TVR, target-vessel revascularization. early restoration of coronary blood flow and subsequent invasive strategy to reopen the infarct-related artery with rescue PCI in case of failed fibrinolysis or to improve the initial results achieved and obviate reocclusion with routine elective PCI in case of successful fibrinolysis. 9 In the FASTMI2015 (French Registry of Acute ST-elevation or Non-ST-elevation Myocardial Infarction 2015), 1714 patients with STEMI (<48 hours) received PPCI, fibrinolysis followed by PCI, or no reperfusion. 13 Time to reperfusion was significantly shorter with fibrinolysis followed by PCI than by PPCI (median, 130 versus 300 minutes). In-hospital or 1-and 5-year mortalities were not different between pharmacoinvasive strategy and PPCI. 13, 14 Recently, the STREAM trial (Strategic Reperfusion Early after Myocardial Infarction) 15 randomly assigned 1892 patients with STEMI within 3 hours of symptom onset and unable to undergo PPCI within 1 hour to either PPCI or fibrinolysis with tenecteplase followed by early coronary angiography within 6 to 24 hours. Thirty-day rates of composite death, shock, congestive heart failure, or reinfarction were similar between fibrinolysis and PPCI arms (12.4% versus 14.3%). At 1 year, mortality rates were similar in both groups. 16 These results suggest that pharmacoinvasive strategy may be an effective alternative option for STEMI treatment when PPCI is not readily available, especially in early presenters. Our results in an Asian population confirm the FASTMI2015 results in a European population and the STREAM results in a North American population.
It is important, however, to note that in pharmacoinvasive strategy the time window between fibrinolysis and PCI is crucial. Facilitated PCI, which refers to pharmacological therapy (usually fibrinolysis or half-dose fibrinolysis plus glycoprotein IIb/IIIa inhibitor) followed by immediate (within 3 hours) planned PCI, was associated with worse outcomes, compared with PPCI. 4, 5 Failure of facilitated PCI may have been attributed to fibrinolysis-induced platelet activation, intraplaque hemorrhage of the culprit lesion, and increased bleeding risk. In addition, the use of suboptimal antithrombotic cotherapy without up-front clopidogrel may have resulted in increased ischemic events. 17 The optimal timing of routine angiography and PCI for pharmacoinvasive strategy has not been determined, but it seems reasonable to perform a coronary angiogram within 3 to 24 hours after successful fibrinolysis in most patients. 2, 3 In the present study, the median time from fibrinolysis and routine elective PCI was 41.5 hours (quartiles, 9.4-77.4 hours). Only 20.5% underwent routine elective PCI within 3 to 24 hours, reflecting a real-world practice of routine elective PCI after successful fibrinolysis performed before the suggested time frame was derived from randomized trials.
The time from symptom onset to reperfusion therapy plays an important role in determining outcomes in STEMI patients. The acceptable time limit for PCI-related delay, beyond which outcomes of PPCI may be less favorable than fibrinolysis with respect to mortality, seems to vary between 60 and 120 minutes. [18] [19] [20] Similarly, in the present study, the equipoise between pharmacoinvasive strategy and PPCI for 12-month MACE occurred when PCI-related delay was ≈100 minutes.
Recent registry data show that the guideline-recommended time goals from FMC to reperfusion in STEMI are often difficult to meet in real practice. An observational study using the Acute Coronary Treatment and Intervention Outcomes Network Registry-Get With the Guidelines database between 2008 and 2012 21 showed that only 51.3% of patients with STEMI (≤12 hours) transferred for PPCI achieved the FMCto-balloon time of ≤120 minutes and 34.3% of fibrinolysis-eligible patients received pretransfer fibrinolysis with only 43.8% achieving a door-to-needle time of ≤30 minutes. Similarly, in the present study, only 45.8% of patients (26.1% of transferred patients) in the PPCI group achieved the FMC-to-balloon time of ≤120 minutes, even though the median door-to-balloon time at STEMI-receiving hospitals (80 minutes) was within the recommended 90 minutes. In the pharmacoinvasive group, the FMC-to-needle time (median, 80 minutes) was much longer than the guideline-recommended 30 minutes. Only 25% of patients achieved a FMC-to-needle time of ≤30 minutes. These findings go to show that the number of STEMI patients treated with delays >120 minutes still remains substantial in real-world circumstances. Fibrinolytic therapy is, however, underutilized among eligible patients, and its administration is often delayed. In the present study, the majority of STEMI patients (70%) had symptom onset-to-FMC ≤3 hours and more than half of the patients (60.4%) have high-risk features (Global Registry of Acute Coronary Events risk score >140). Given that only 23% of transferred patients receiving PPCI in the propensity-matched cohort achieved FMC-to-balloon time ≤120 minutes, as many as 3 quarters of fibrinolysis-eligible patients being transferred in our STEMI network would benefit from pharmacoinvasive strategy. Hazard ratios (HR) for 12-month major adverse cardiac events in propensity-matched cohort according to subgroup. CI indicates confidence interval; EMS, emergency medical system; GRACE, Global Registry of Acute Coronary Events; HR, hazard ratio; PI, pharmacoinvasive; and PPCI, primary percutaneous coronary intervention.
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The present study has the usual limitations inherent in observational studies. Although these results come from a large cohort and adjustment was made using propensity score analysis for a large number of confounding variables, unmeasurable factors may still exist. Patients receiving PPCI had higher estimated mortality risk than patients treated with pharmacoinvasive strategy based on comparisons of measured clinical characteristics, indicating that treating physicians may have preferred PPCI for higher-risk patients, even when longer FMC-to-balloon times were expected.
In conclusion, in this large observational study with propensity-matched analysis, STEMI patients receiving pharmacoinvasive strategy, compared with PPCI, had shorter symptom-to-reperfusion time, higher culprit-vessel patency, and similar 12-month clinical outcome. Still, many transferred patients with STEMI fail to undergo timely PPCI but fibrinolysis is being underutilized. With the growing number of high-risk STEMI patients presenting early, pharmacoinvasive strategy seems to have a crucial part to play and is probably a realistic alternative to reduce total ischemic time and infarct mortality.
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